Status:
COMPLETED
Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
Eligibility Criteria
Inclusion
- Moderate to severe idiopathic RLS
- symptoms occur predominantly in the evening
- symptoms interfere with sleep onset or maintenance
Exclusion
- Any secondary RLS
- require treatment for daytime RLS symptoms
- symptomatic neuropathies
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT00676403
Start Date
April 1 2008
End Date
January 1 2009
Last Update
February 10 2021
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tuscaloosa, Alabama, United States, 35406
2
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
3
Pfizer Investigational Site
San Diego, California, United States, 92121
4
Pfizer Investigational Site
Santa Monica, California, United States, 90404